Home  |   Archive  |   Online Submission  |   News & Events  |   Subscribe  |   APFA  |   Society  |   Contact Us  |   中文版
Search   
 
Journal

Ahead of print
Authors' Accepted
    Manuscripts
new!
Current Issue
Archive
Acknowledgments
Special Issues
Browse by Category

Manuscript Submission

Online Submission
Online Review
Instruction for Authors
Instruction for Reviewers
English Corner new!

About AJA

About AJA
Editorial Board
Contact Us
News

Resources & Services

Advertisement
Subscription
Email alert
Proceedings
Reprints

Download area

Copyright licence
EndNote style file
Manuscript word template
Guidance for AJA figures
    preparation (in English)

Guidance for AJA figures
    preparation (in Chinese)

Proof-reading for the
    authors

AJA Club (in English)
AJA Club (in Chinese)

 
Abstract

Volume 15, Issue 4 (July 2013) 15, 445–446; 10.1038/aja.2013.57

Androgen-deprivation therapy in men with metastatic prostate cancer: less may not necessarily be more

Mark Ng Tang Fui1,2 and Mathis Grossmann1,2

1 Department of Medicine, University of Melbourne Austin Health, Heidelberg, Victoria 3084, Australia
2 Endocrinology, Austin Health, Heidelberg, Victoria 3084, Australia

advance online publication, May 20, 2013

Abstract

In a pivotal phase 3 randomized controlled trial, Hussain et al. tested the hypothesis that, with respect to survival, intermittent androgen deprivation therapy (ADT) is non-inferior to continuous in men with newly diagnosed metastatic prostate cancer. While the trial findings were statistically inconclusive, the study suggests, but does not prove, that intermittent may do more harm than good, although findings are not definitive. While outcomes of ongoing trials are awaited, the trial by Hussain et al., in conjunction with an earlier trial in men with non-metastatic prostate cancer by Crook et al., does provide important new guidance regarding the choice of ADT in men with androgen-sensitive prostate cancer.

PDF | PDF |

 
Browse:  2795
 
Asian Journal of Andrology CN 31-1795/R ISSN 1008-682X  Copyright © 2023  Shanghai Materia Medica, Chinese Academy of Sciences.  All rights reserved.